



OMB No. 0651-0011

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

Atty. Docket No.	0084370035	Serial No.	09/803,918
Applicant	Jean-Michel DAYER et al.		
Filing Date	March 13, 2001	Group:	<del>1645</del> 1644

**RECEIVED**

FEB 28 2002

TECH CENTER 1600/2900

**U.S. PATENT DOCUMENTS**

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Sub Class	Translation Yes or No
Pkt	WO 96/37608	11/28/96	PCT			No (English Abstract)
↓	WO 99/16409	04/08/99	PCT			
↓	WO 93/07165	04/15/93	PCT			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Pkt	HAMIDI ASL et al.; A Novel Apolipoprotein A-1 Variant, Arg173Pro, Associated With Cardiac And Cutaneous Amyloidosis; Biochemical and Biophysical Research Communications 257, pp. 584-588 (1999).
↓	DAYER et al.; Apolipoprotein A-1 Inhibits IL-1 $\beta$ And TNF- $\alpha$ Production by Blocking Contact-Mediated Activation Of Monocytes By T Lymphocytes; Arthritis and Rheumatism, 43, p. 1726 (2000).
↓	HYKA et al.; Apolipoprotein A-I inhibits the production of interleukin-1 $\beta$ and tumor necrosis factor- $\alpha$ by blocking contact-mediated activation of monocytes by T lymphocytes; Blood, 97, pp. 2381-2389 (2001).

Examiner	Date Considered
	10/7/02
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce

**INFORMATION DISCLOSURE CITATION**  
(Use several sheets if necessary)

OMB No. 0651-0011

Atty. Docket No. 06843.0035	Serial No. 09/803,918
Applicant Jean-Michel DAYER, et al.	
Filing Date March 13, 2001	Group: 1645 1644

**U.S. PATENT DOCUMENTS**


Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

Document Number	Date	Country	Class	Sub Class	Translation Yes or No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

PSA	Bruhn, H., et al., "An Approach To The Functional Analysis Of Lecithin-Cholesterol Acyltransferase. Activation By Recombinant Normal And Mutagenized Apolipoprotein AI," <i>Biol. Chem. Hoppe-Seyler</i> , 372:225-234, 1991. ✓
	McGuire, K. A., et al., "High Yield Overexpression And Characterization Of Human Recombinant Proapolipoprotein A-I," <i>J. Lipid Res.</i> , 37:1519-1528, 1996. ✓
	Moguilevsky, N., et al., "Production Of Authentic Human Proapolipoprotein A-I In Escherichia Coli: Strategies For The Removal Of The Amino-Terminal Methionine," <i>J. Biotechnol.</i> 27:159-172, 1993. ✓
	Moguilevsky, N., et al., "Production Of Human Recombinant Proapolipoprotein, A-I In Escherichia Coli : Purification And Biochemical Characterization," <i>DNA</i> 8:429-436, 1989.
	Pyle, L. E., et al., "Structural And Functional Properties Of Full-Length And Truncated Human Proapolipoprotein AI Expressed In Escherichia Coli," <i>Biochemistry</i> 35:12046-12052, 1996. ✓
✓	Sirtori, C. R., et al., "Recombinant Apolipoproteins For The Treatment Of Vascular Diseases," <i>Atherosclerosis</i> 142:29-40, 1999.

Examiner 	Date Considered Oct 7, 2002
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449 Patent and Trademark Office - U.S. Department of Commerce	